Skip to Main Content

Author Details

Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
2005
171
42
PMIDPaper TitleJournal TitlePublished Year
36346458Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).Virchows Arch2023
37996705Glyoxal acid-free (GAF) histological fixative is a suitable alternative to formalin: results from an open-label comparative non-inferiority study.Virchows Arch2023
37993874CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.J Exp Clin Cancer Res2023
37769528DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.Neoplasia2023
35858535Tissue Fixation with a Formic Acid-Deprived Formalin Better Preserves DNA Integrity over Time.Pathobiology2023
37129948BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.Cancer Res2023
36816936Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.Front Oncol2023
36853785Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features.Mod Pathol2023
36622698Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.Clin Cancer Res2023
36584674Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.Cancer Cell2023
36834912The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.Int J Mol Sci2023
36831541ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations.Cancers (Basel)2023
36527467Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).Virchows Arch2023
36527253TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.Histopathology2023
36413222HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.Clin Cancer Res2023
33148628Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites.J Clin Pathol2022
35741073The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients.Cells2022
35500561Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives.Pathobiology2022
35454806Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.Cancers (Basel)2022
36590146HER2-Low Breast Cancer: Where Are We?Breast Care (Basel)2022
36142281Integrated Antitumor Activities of Cellular Immunotherapy with CIK Lymphocytes and Interferons against KIT/PDGFRA Wild Type GIST.Int J Mol Sci2022
36243799Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.Virchows Arch2022
36038884Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Genome Med2022
36056393The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway.J Exp Clin Cancer Res2022
36379199PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.Breast2022
35882101Timing evolution of lobular breast cancer through phylogenetic analysis.EBioMedicine2022
35915157Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.Nat Med2022
35043236Incorporation of TILs in daily breast cancer care: how much evidence can we bear?Virchows Arch2022
34918596Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.Tumori2022
35053395Tumoral Neuroligin 1 Promotes Cancer-Nerve Interactions and Synergizes with the Glial Cell Line-Derived Neurotrophic Factor.Cells2022
35260767Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors.NPJ Precis Oncol2022
34458945Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.Virchows Arch2022
32112814Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.Semin Cancer Biol2021
33542076Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas.Clin Cancer Res2021
33762723Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ⿥2.0, HER2 copy number &lt;4.0 signals/cell) cases.Br J Cancer2021
33672732Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.Cancers (Basel)2021
33842357<i>PIK3CA</i> Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.Front Oncol2021
33755862Personalized therapeutic strategies in HER2-driven gastric cancer.Gastric Cancer2021
33660227Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach?Pharmacoecon Open2021
34496925HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.J Hematol Oncol2021
34638258Molecular Characterization of Prostate Cancers in the Precision Medicine Era.Cancers (Basel)2021
34463674Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.Pathologica2021
34837093"Borderline" epithelial lesions of the breast: what have we learned in the past three decades?Pathologica2021
34503219Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer.Cancers (Basel)2021
34218258Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.Mod Pathol2021
34217971Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.Breast2021
34203156Special Issue: Molecular Biomarkers in Solid Tumors.Genes (Basel)2021
34359705Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways.Cancers (Basel)2021
34359596Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.Cancers (Basel)2021
34282766Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients.Cancers (Basel)2021
  • 1 - 50 of 171

Recommended Authors

Joanna Cyrta
Paris Sciences Lettres University PSL, Institut CURIE
Career Start Year 2012
Number of shared co-authors 11
Francisco Beca
Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 10
Myriam Kossai
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 7
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 3
Leonard Da Silva
Pathology Queensland The Royal Brisbane and Women's Hospital Brisbane Qld Australia.
Career Start Year 2007
Number of shared co-authors 5
Pamela J Provan
Westmead Institute for Medical Research, Westmead Hospital, The University of Sydney
Career Start Year 2006
Number of shared co-authors 0
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 5
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 7
Peter T Simpson
UQ Centre for Clinical Research, The University of Queensland
Career Start Year 2003
Number of shared co-authors 6
Juan Miguel Mosquera
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2002
Number of shared co-authors 10
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 3
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 1
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 2
Timo Gaiser
Institut fur Pathologie, Universitatsmedizin Mannheim
Career Start Year 2000
Number of shared co-authors 0
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 5
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Ronald Simon
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1996
Number of shared co-authors 5
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 3
David G Huntsman
University of British Columbia
Career Start Year 1994
Number of shared co-authors 12
Rosemary L Balleine
Westmead Institute for Medical Research, The University of Sydney
Career Start Year 1993
Number of shared co-authors 3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 9
Guido Sauter
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1990
Number of shared co-authors 5
Eberhard Korsching
Institutet of Bioinformatics, University Hospital of Munster, University of Munster
Career Start Year 1990
Number of shared co-authors 5
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 10
Elizabeth Mallon
Queen Elizabeth University Hospital
Career Start Year 1986
Number of shared co-authors 2
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 8
Sunil R Lakhani
University of Queensland
Career Start Year 1983
Number of shared co-authors 13
Hans-Peter Sinn
Pathologisches Institut, Universitatsklinikum Heidelberg
Career Start Year 1981
Number of shared co-authors 6
David L Rimm
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 11

Collaborators

Jorge S Reis-Filho
Memorial Sloan-Kettering Cancer Center
Co-authored papers 47
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Co-authored papers 22
Felipe C Geyer
Instituto Do Cancer Do Estado de Sao Paulo
Co-authored papers 17
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 16
Salvatore Piscuoglio
University of Basel
Co-authored papers 14
Charlotte K Y Ng
University of Bern
Co-authored papers 14
Alan Mackay
Co-authored papers 12
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 12
Larry Norton
Memorial Sloan Kettering Cancer Center
Co-authored papers 9
Nicola Fusco
IEO European Institute of Oncology IRCCS
Co-authored papers 9
Hannah Y Wen
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Co-authored papers 8
Kathleen A Burke
Brown University
Co-authored papers 7
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Jos?? Palacios
Universidad de Alcala
Co-authored papers 6
Christos Sotiriou
Co-authored papers 5
Luciano G Martelotto
Monash University
Co-authored papers 4
Melissa P Murray
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Robert A Soslow
Co-authored papers 4
Brian P Rubin
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic
Co-authored papers 4
Raymond S Lim
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Alberto Zambelli
IRCCS Humanitas Research Hospital
Co-authored papers 3
Carmen Criscitiello
University of Milano
Co-authored papers 3
Pier Selenica
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Alena Sk??lov??
Charles University
Co-authored papers 2
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 2
Souzan Sanati
Co-authored papers 2
Elisabetta Marangoni
Co-authored papers 2
Reza Mirzazadeh
KTH Royal Institute of Technology
Co-authored papers 2
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Co-authored papers 2
Release 1.2